Cas:116425-36-6 2-Isopropylidene-6-methyl-5-(3-oxobutyl)-4-cyclohepten-1-one manufacturer & supplier

Chemical Name:2-Isopropylidene-6-methyl-5-(3-oxobutyl)-4-cyclohepten-1-one

CAS.NO:116425-36-6

Synonyms:4-Cyclohepten-1-one, 6-methyl-2-(1-methylethylidene)-5-(3-oxobutyl)-, (6S)-;(6S)-2-Isopropylidene-6-methyl-5-(3-oxobutyl)-4-cyclohepten-1-one;Curcumadione

Molecular Formula:C₁₅H₂₂O₂

Molecular Weight:234.334

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:359.4±42.0 °C at 760 mmHg

Density:1.0±0.1 g/cm3

Index of Refraction:1.482

PSA:

Exact Mass:234.161987

LogP:2.66

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-Cyclohepten-1-one, 6-methyl-2-(1-methylethylidene)-5-(3-oxobutyl)-, (6S)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Curcumadione physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(6S)-2-Isopropylidene-6-methyl-5-(3-oxobutyl)-4-cyclohepten-1-one Use and application,Curcumadione technical grade,usp/ep/jp grade.

Related News: A new post-hoc analysis of pooled data from the TULIP phase III clinical trials being presented at the annual European Congress of Rheumatology (EULAR 2021) showed anifrolumab was consistently associated with improvements in both skin rash and arthritis across three different disease measures each, compared to placebo, in patients with moderate to severe systemic lupus erythematosus (SLE). (4-chlorophenyl)(8-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-pyrrolo[3,2-g]isoquinolin-1-yl)methanone manufacturers Though the program obtained priority review from FDA back in November, analysts expressed skepticism in July 2020 after it failed to prove superior to the companies’ other drug Lumizyme in improving respiratory function in a Phase III trial. Poly[(3-oxo-1(3H)-isobenzofuranylidene)-1,4-phenyleneoxy-1,4-phenylene(methylphosphinylidene)-1,4-phenyleneoxy-1,4-phenylene] suppliers He joins us at a pivotal time as our Jinkō® platform goes from strength to strength as we expand our portfolio of partnerships. Grégoire’s strategic and operational expertise will be a vital part of our future success in accelerating and de-risking clinical trials. N-((1R,3R)-3-((S)-1-amino-2-oxo-2-(pyrrolidin-1-yl)ethyl)cyclopentyl)benzene-1,4-disulfonamide vendor & factory.